Lyell Immunopharma Inc is a clinical-stage cell therapy company... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
LYEL is expected to report earnings to fall 8.46% to -16 cents per share on August 06
Q2'25
Est.
$-0.16
Q1'25
Missed
by $0.01
Q4'24
Missed
by $0.51
Q3'24
Beat
by $0.01
Q2'24
Est.
$-0.18
The last earnings report on May 13 showed earnings per share of -17 cents, missing the estimate of -17 cents. With 1.31M shares outstanding, the current market capitalization sits at 132.38M.